Healthcare bid: if defensives rotate, who leads—managed care or big pharma?
With policy rates likely to ease into year-end, investors often rotate toward “defensives.” In healthcare, that typically means managed care (health insurers) and big pharma. But 2025’s cross-currents—Medicare Advantage (MA)…